^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Hematological Malignancies

    Related cancers:
    1d
    NCI-2021-09185: Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=24, Recruiting, City of Hope Medical Center | Trial completion date: Feb 2026 --> May 2026 | Trial primary completion date: Feb 2026 --> May 2026
    Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • cytarabine • cyclophosphamide • methotrexate • vincristine • daunorubicin • Oncaspar liquid (pegaspargase) • mercaptopurine • Starasid (cytarabine ocfosfate)
    1d
    CiproPAL (Ciprofloxacin Prophylaxis in Acute Leukaemia) (clinicaltrials.gov)
    P=N/A, N=313, Active, not recruiting, University College, London | N=1052 --> 313 | Trial completion date: Dec 2031 --> Jun 2028 | Trial primary completion date: Dec 2025 --> Jan 2028 | Recruiting --> Active, not recruiting
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    1d
    Venetoclax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mutated AML (clinicaltrials.gov)
    P1/2, N=29, Recruiting, The First Affiliated Hospital of Soochow University
    New P1/2 trial
    |
    CEBPA (CCAAT Enhancer Binding Protein Alpha)
    |
    Venclexta (venetoclax) • cytarabine • azacitidine
    1d
    A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P2, N=80, Recruiting, City of Hope Medical Center | Trial completion date: Jan 2026 --> Jan 2029 | Trial primary completion date: Jan 2026 --> Jan 2029
    Trial completion date • Trial primary completion date
    |
    IL4 (Interleukin 4)
    1d
    Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=24, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date
    |
    CD4 (CD4 Molecule)
    |
    Rituxan (rituximab) • bortezomib • alisertib (MLN8237) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar)
    1d
    Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients (clinicaltrials.gov)
    P2, N=27, Active, not recruiting, City of Hope Medical Center | Recruiting --> Active, not recruiting | N=56 --> 27 | Trial completion date: Jul 2026 --> Jan 2027 | Trial primary completion date: Jul 2026 --> Jan 2027
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    leflunomide
    1d
    Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer (clinicaltrials.gov)
    P2, N=15, Active, not recruiting, University Health Network, Toronto | Recruiting --> Active, not recruiting | Trial completion date: Jun 2026 --> Dec 2026 | Trial primary completion date: Jan 2026 --> Dec 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    1d
    Disease Burden Transition of Mucormycosis in Hematologic Malignancies Population Across Covid 19 Era: a Single-center Comparative Analysis From China (clinicaltrials.gov)
    P=N/A, N=60, Completed, Institute of Hematology & Blood Diseases Hospital, China | Active, not recruiting --> Completed | Trial completion date: Oct 2025 --> May 2025
    Trial completion • Trial completion date
    1d
    DARATALL-VHR: Daratumumab in VHR T-ALL Treated According to the ALL National Treatment Program (clinicaltrials.gov)
    P2, N=31, Active, not recruiting, Gruppo Italiano Malattie EMatologiche dell'Adulto | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD38 (CD38 Molecule)
    |
    cyclophosphamide • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    1d
    SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas (clinicaltrials.gov)
    P1/2, N=48, Recruiting, University of California, San Diego | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    |
    Rituxan (rituximab)
    1d
    A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
    P1, N=36, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    FLT3 (Fms-related tyrosine kinase 3) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    IDH1 mutation • IDH2 mutation • FLT3 mutation
    |
    Xospata (gilteritinib) • Tibsovo (ivosidenib) • Idhifa (enasidenib)
    1d
    PKBMT: Precision Dosing of Anti-Cancer Medicines for patients undergoing Oncology, Blood Transplant and Cellular Therapies. (ACTRN12626000285358)
    P=N/A, N=300, Not yet recruiting, The Children's Hospital at Westmead
    New trial
    |
    fludarabine IV • Grafapex (treosulfan)